Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Treatment of Graves’ Disease with Combination Therapy: A Chart Review Reba Leonard Introduction Graves’ Disease is the most common autoimmune disorder and affects approximately 1% of the United States population. An autoimmune disorder is when the immune system, the body’s main defense against pathogens, mistakes healthy body tissue as a foreign invader and attacks the tissue. In the case of Graves’ disease, the immune system attacks the thyroid gland. The thyroid gland, a part of the endocrine system, releases hormones, which control metabolism, heart rate, and mood. In most cases, when the thyroid gland is attacked by the immune system, the antibodies attach to the thyrotropin receptors and activate the thyroid gland (Weetman, 2000, 1236). This causes the hypertrophy of the thyroid gland and excess hormones to be released. When excess thyroid hormones are released the body’s metabolism speeds up, causing one of the most common symptoms of Graves’ disease, weight loss. Other symptoms include fatigue, anxiety, depression, heat intolerance, palpitations (irregular heartbeat), goiter (swelling of the thyroid gland), fertility problems, and ophthalmopathy, which is characterized by swelling of the muscles of the eye and results in double vision and can sometimes lead to blindness (Scharf, 2006, 902). Graves’ Disease is treated by first correcting the hyperthyroidism associated with Graves’ disease. This can be done by a thyroidectomy, radioactive iodine, or antithyroid medication (Cinemre, 2009, 199). However, both surgery and radioactive iodine have been known to increase ophthalmopathy. Surgery is an invasive procedure, and potentially risky because it can cause laryngeal nerve injury, leading to difficulty speaking (Scharf, 2006, 902). Radioactive iodine, the favored therapy in the United States, is ingested orally and absorbed by the thyroid gland, because the thyroid gland uses iodine to make hormones. The radioactive iodine then irradiates the cells that take it in, thus killing them (Ogbera, 2008, 212). Radioactive iodine, as well as surgery, can render a patient hypothyroid, because they no longer have a thyroid gland to produce hormones (Scharf, 2006, 902). As a result, they will have to be on thyroid medications for the rest of their life (Scharf, 2006, 902). Anti-thyroid medications are more likely to improve the condition due to a blocking of antibodies. However, because the medication reduces the amount of thyroid hormones, sometimes the patient still becomes hypothyroid, which can exacerbate the ophthalmopathy. Also, once the patients terminate treatment, they can experience recurrent hyperthyroidism, which can also worsen ophthalmopathy (Lowery, 2009, 292). This project studied the combination therapy of two medications, methimazole, an anti-thyroidal/immunosuppressive medication, and L-thyroxine, a thyroid hormone replacement medication. It is expected that the combination therapy will be more beneficial than the other treatment options for Graves’ Disease. Advisor: Dr. Hancock Figure 1: A box plot of white blood cell counts in the different treatment types. The shaded box represents the normal range of white blood cells. There was a significant difference between the combination therapy treatment and the rest of the treatment groups, and between the thyroidectomy treatment and the rest of the treatment groups. However, the majority of patients in each treatment type were within the recommended ranges for white blood cell count, which means that the treatments are not negatively affecting the numbers of immune cells in the body. Figure 3: A box plot of the levels of free T4, which is a hormone released from the thyroid gland, for each treatment type. There was a significant difference between the combination therapy treatment and the rest of the treatment groups, between the thyroidectomy treatment and the rest of the treatment groups, and between the synthyroid treatment and the rest of the treatment groups. All treatment types were within the normal range, which means that the treatments are regulating the synthesis and release of thyroid hormones. Conclusions In conclusion, the obtained results partially support the hypothesis that combination therapy will result in a significantly different outcome than the other treatment options for Graves’ Disease. Combination therapy had a significantly different white blood cell count, thyroid stimulating hormone levels, and free T4 levels than the other treatment types, although none were out of the recommended levels. However, combination therapy resulted in relatively the same outcomes as the other treatment types, for neutrophil count, TSI and TBI. General Methodology The effect of combination therapy was investigated by conducting chart reviews at outpatient offices at Ohio University and Belpre Endocrinology Center. The data that was recorded was patient number, treatment type, white blood cell count, neutrophil count, thyroid-stimulating hormone, free T4, thyroid-stimulating immunoglobulin, and thyrotropin binding inhibitor for 7 different treatment types: combination therapy, thyroidectomy, radioactive iodine, synthyroid (hormone replacement medication), anti-thyroid medication, no treatment and remission. Each variable was compared between treatment groups using a one way ANOVA. Any variables that did result in a significant difference were then analyzed with post hoc t-tests to determine which treatment groups differed. Table 1: The results of the comparisons of each variable between treatment types. Literature Cited Cinemre H, Bilir C, Gokosmangolu F, Akdemir N, Erdogmus B, Buyukkaya R. 1999. Predictors of time to remission and treatment failure in patients with Graves’ disease treated with propylthiouracil. Clinical and Investigative Medicine, 32(3): 199-205. Lowery AJ, Kerin MJ. 2009. Graves’ Opthalmopathy: The case for thyroid surgery. Surgeon, 7(5): 290-296. Ogbera AO, Ekpebegh C, Eregie A, Kuku SF. 2008. The Role of radioactive iodine usage in the management of thyroid disorders with emphasis on Sub-Saharan Africa. The West African Journal of Medicine, 27(4): 211-217. Scharf JL, Ahmad SM, Gaughan JP, Soliman AMS. 2006. Thyroidectomy for Graves’ Disease: A Case-Control Study. Annals of Otology, Thinology & Laryngology, 115(12): 902-907. Weetman AP. 2010. Medical Progress: Graves’ Disease. The New England Journal of Medicine, 343(17): 1236-48. Results Results Figure 2: A box plot of thyroid-stimulating hormone (TSH) levels in the different treatment types. There was a significant difference between the combination therapy treatment and the rest of the treatment groups, and between the thyroidectomy treatment and the rest of the treatment groups. Most of the treatment types were not within the recommended range (shaded box) of TSH. This is expected since the main objective of each treatment is to decrease the level of thyroid hormones released, and a decrease in thyroid hormones causes an increase in TSH. Variable Significant Difference? Which Treatments are Different? WBC Yes (p=0.02) 1 differed from 2-7 2 differed from 1, 3-7 Neutrophils TSH No Yes (p<0.001) Free T4 Yes (p<0.001) TSI No None 1 differed from 2-7 2 differed from 1, 3-7 1 differed from 2-7 2 differed from 1, 3-7 4 differed from 1-3, 5-7 None TBI No None Treatment types: 1 = Combination therapy, 2 = thyroidectomy, 3 = I-123 (radioactive iodine), 4 = Synthyroid, 5 = Antithyroid, 6 = None, 7 = Remission Acknowledgments I would like sincerely thank all of those who helped me in this project. I greatly appreciate all that Dr. Hancock has done for me and this project. She has been a wonderful advisor. I would also like to thank Dr. McShaffrey for being a great capstone class advisor. Also, a thanks is due to my capstone classmates for their support, direction, and constructive criticism. Most importantly, a thanks goes out to my friends and family for supporting me through it all!